ClinicalTrials.gg
CompletedNCT05444569Updated Mar 1, 2023

A Study of LY3537021 in Healthy Participants

A Phase 1 interventional study of LY3537021 and Liraglutide in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-01.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy participants. The study will include 2 parts. The study will last up to 16 and 22 weeks for part A and B, respectively which includes a screening period of 6 weeks.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined through medical evaluation
  • Participants with body weight at least 55 kilograms (kg) and (BMI) of 23.0 to 40.0 kilograms per meter squared (kg/m²)
  • Males, or females who are not of .
  • Capable of giving signed form
  • Have blood pressure of less than 150/90 millimeters of mercury (mm Hg) and pulse rate of less than 100 beats per minute (bpm) (supine)

Exclusion criteria

Exclusion Criteria:

  • Have a significant history of current disorders capable of significantly altering the absorption, metabolism or elimination of drugs
  • History of within 5 years prior to screening
  • Have evidence of significant active psychiatric disorder(s)
  • Have undergone any form of bariatric surgery
  • Have an abnormality in the 12-lead (ECG)
  • Are females who are lactating
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    LY3537021 + Liraglutide (Part A)

    Liraglutide administered subcutaneously (SC) followed by liraglutide in combination with LY3537021 given SC.

    Drug: LY3537021 · Drug: Liraglutide

  • Experimental
    Liraglutide + Placebo (Part A)

    Liraglutide administered SC followed by liraglutide in combination with placebo given SC.

    Drug: Liraglutide · Drug: Placebo

  • Experimental
    LY3537021 + Liraglutide & Placebo + Liraglutide (Part B)

    LY3537021 administered SC followed by liraglutide administered SC in treatment period 1. Placebo administered SC followed by liraglutide administered SC in treatment period 2.

    Drug: LY3537021 · Drug: Liraglutide · Drug: Placebo

  • Experimental
    Placebo + Liraglutide & LY3537021 + Liraglutide Part B)

    Placebo administered SC followed by liraglutide administered SC in treatment period 1. LY3537021 administered SC followed by liraglutide administered SC in treatment period 2.

    Drug: LY3537021 · Drug: Liraglutide · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Week 22

07

Study locations

1 site
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Feb 2023, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 6, 2022
StartActual
Aug 8, 2022
Primary completionActual
Feb 24, 2023
CompletionActual
Feb 24, 2023
Last update
Mar 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05444569
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Aug 8, 2022
Primary completion
Feb 24, 2023
Completion
Feb 24, 2023
Last update
Mar 1, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GIPR Agonist LY3537021

Start the discussion